Entering text into the input field will update the search result below

Predictive Oncology: Potentially Undervalued Drug Discovery AI Company

Ari Zoldan profile picture
Ari Zoldan


  • There is growing demand for AI use in drug development.
  • Drug development deals go from $5 million to over $1 billion.
  • Predictive Oncology has a unique platform using real patient samples in its AI process.
  • Predictive Oncology could be undervalued if it can ink large or multiple drug development contracts.

In this article, we highlight the trend in the pharmaceutical industry to use AI during the R&D process to improve investment returns by cutting costs and improving chances of success. A substantial number of drug discovery deals have been made in recent years with deal values ranging from $5 million to over $1 billion, with a skew towards the lower end. Venture capital has poured billions into this AI and ML space in recent years, with a recent report that over $10 billion was raised for artificial intelligence and machine learning, driven by drug discovery and diagnostics AI/ML funding in Q3 2020. The healthcare AI market segment is expected to boom in the coming years. Here, we highlight Predictive Oncology, a microcap biopharma AI company focused on oncology, with unique assets that differentiate it from other oncology AI companies. We believe the company could be undervalued, as it has valuable assets that we believe nobody else in the world has.


A slew of biotech deals in recent years utilizing AI for drug discovery and development has highlighted the opportunity to improve success rates (getting a drug to approval) for pharmaceuticals and biotech R&D, as returns on investment have dropped to the lowest levels in years, and chances of clinical success from drugs passing discovery and preclinical studies remain low. One reason is that average peak sales estimates are still moving down while costs to bring drugs to market are increasing. Thus, an important aspect to increasing IRRs is efficiently driving R&D. Eroom’s Law, that the drug R&D process is getting more expensive and longer over time, appears well at work.

Source: A new future for R&D? Measuring the return from pharmaceutical innovation. Deloitte.

Pharma Improving R&D With AI

The industry is now turning to artificial intelligence to improve its

This article was written by

Ari Zoldan profile picture
Ari Zoldan is the CEO of Quantum Media Group, a marketing and media agency based in New York City. As an on-air TV personality, Ari can be seen regularly on FOX, CNN & CNBC covering technology, media and business trends. Ari serves as Chair of the Media & Development committee for The Zahn Center for Innovation at City College. In his journalistic capacity Ari and has been to dozens of war torn and conflicted zones such as South Sudan, Uganda, Nicaragua, Haiti, Burma, & Guinea. He holds press credentials on Capitol Hill and the United Nations and is a member of the National Press Club in Washington, DC.

Analyst’s Disclosure: I am/we are long POIA. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.